Baillie Gifford & CO Bei Gene, Ltd. Transaction History

Baillie Gifford & CO

  • $126 Billion
  • Q2 2024

A detailed history of Baillie Gifford & CO transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Baillie Gifford & CO holds 3,681,949 shares of BGNE stock, worth $752 Million. This represents 0.42% of its overall portfolio holdings.

Number of Shares
3,681,949
Previous 3,728,730 1.25%
Holding current value
$752 Million
Previous $583 Million 9.92%
% of portfolio
0.42%
Previous 0.46%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 25, 2024
SELL
$129.52 - $174.32 $6.06 Million - $8.15 Million
-46,781 Reduced 1.25%
3,681,949 $525 Million
Q1 2024

May 01, 2024
SELL
$141.8 - $181.47 $19.5 Million - $25 Million
-137,719 Reduced 3.56%
3,728,730 $583 Million
Q4 2023

Jan 26, 2024
SELL
$158.67 - $201.58 $816,991 - $1.04 Million
-5,149 Reduced 0.13%
3,866,449 $697 Million
Q3 2023

Nov 13, 2023
BUY
$179.87 - $225.13 $106 Million - $132 Million
588,294 Added 17.92%
3,871,598 $696 Million
Q2 2023

Jul 28, 2023
SELL
$178.3 - $266.78 $6.07 Million - $9.09 Million
-34,058 Reduced 1.03%
3,283,304 $585 Million
Q1 2023

May 03, 2023
SELL
$215.53 - $274.5 $19.7 Million - $25.1 Million
-91,357 Reduced 2.68%
3,317,362 $715 Million
Q4 2022

Jan 24, 2023
BUY
$125.51 - $229.3 $24.9 Million - $45.6 Million
198,778 Added 6.19%
3,408,719 $750 Million
Q3 2022

Oct 27, 2022
SELL
$131.8 - $202.24 $3.29 Million - $5.05 Million
-24,990 Reduced 0.77%
3,209,941 $433 Million
Q2 2022

Aug 08, 2022
SELL
$121.11 - $216.05 $105 Million - $188 Million
-868,037 Reduced 21.16%
3,234,931 $524 Million
Q1 2022

May 05, 2022
SELL
$146.52 - $269.56 $3.07 Million - $5.64 Million
-20,931 Reduced 0.51%
4,102,968 $774 Million
Q4 2021

Jan 20, 2022
SELL
$248.56 - $389.34 $31.1 Million - $48.7 Million
-125,153 Reduced 2.95%
4,123,899 $1.12 Billion
Q3 2021

Oct 19, 2021
SELL
$249.6 - $403.14 $5.77 Million - $9.32 Million
-23,126 Reduced 0.54%
4,249,052 $1.54 Billion
Q2 2021

Aug 02, 2021
SELL
$292.75 - $367.01 $45.8 Million - $57.5 Million
-156,537 Reduced 3.53%
4,272,178 $1.47 Billion
Q1 2021

May 06, 2021
BUY
$260.64 - $382.12 $47.1 Million - $69.1 Million
180,888 Added 4.26%
4,428,715 $1.54 Billion
Q4 2020

Feb 10, 2021
BUY
$221.31 - $316.61 $622 Million - $891 Million
2,812,638 Added 195.98%
4,247,827 $1.1 Billion
Q3 2020

Nov 12, 2020
BUY
$189.18 - $286.44 $210 Million - $318 Million
1,109,006 Added 340.0%
1,435,189 $411 Million
Q2 2020

Aug 12, 2020
BUY
$123.9 - $195.41 $2.99 Million - $4.72 Million
24,160 Added 8.0%
326,183 $61.5 Million
Q1 2020

May 08, 2020
BUY
$121.84 - $173.19 $1.63 Million - $2.31 Million
13,348 Added 4.62%
302,023 $37.2 Million
Q4 2019

Feb 10, 2020
SELL
$115.78 - $208.34 $23.2 Million - $41.7 Million
-200,219 Reduced 40.95%
288,675 $47.9 Million
Q3 2019

Nov 07, 2019
BUY
$120.61 - $148.29 $47.1 Million - $57.9 Million
390,370 Added 396.22%
488,894 $59.9 Million
Q2 2019

Aug 08, 2019
BUY
$113.99 - $146.86 $336,270 - $433,237
2,950 Added 3.09%
98,524 $12.2 Million
Q1 2019

May 01, 2019
BUY
$122.82 - $151.83 $105,379 - $130,270
858 Added 0.91%
95,574 $0
Q4 2018

Feb 14, 2019
BUY
$107.01 - $175.15 $1.38 Million - $2.27 Million
12,938 Added 15.82%
94,716 $13.3 Million
Q3 2018

Nov 13, 2018
SELL
$152.62 - $189.66 $250,449 - $311,232
-1,641 Reduced 1.97%
81,778 $14.1 Million
Q2 2018

Jul 17, 2018
SELL
$152.5 - $216.77 $609,695 - $866,646
-3,998 Reduced 4.57%
83,419 $12.8 Million
Q1 2018

May 10, 2018
BUY
$97.41 - $177.22 $16,170 - $29,418
166 Added 0.19%
87,417 $14.7 Million
Q4 2017

Feb 13, 2018
BUY
$79.6 - $114.73 $576,383 - $830,759
7,241 Added 9.05%
87,251 $8.53 Million
Q3 2017

Oct 20, 2017
BUY
$66.19 - $103.46 $369,737 - $577,927
5,586 Added 7.51%
80,010 $8.28 Million
Q2 2017

Aug 10, 2017
BUY
N/A
74,424
74,424 $3.35 Million

Others Institutions Holding BGNE

# of Institutions
217
Shares Held
42.1M
Call Options Held
106K
Put Options Held
93.1K
View Full List

About BeiGene, Ltd.

BGNE Quotes by TradingView
  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $21.2B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Baillie Gifford & CO Portfolio

Follow Baillie Gifford & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

News

Stay updated on Baillie Gifford & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email